Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers by Ammelie Svea Boje, Lukas Pekar, Katharina Koep, Britta Lipinski, Brian Rabinovich, Andreas Evers, Carina Lynn Gehlert, Steffen Krohn, Yanping Xiao, Simon Krah, Rinat Zaynagetdinov, Lars Toleikis, Sven Poetzsch, Matthias Peipp, Stefan Zielonka, Katja Klausz

Subjects: Get full text

A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy by Gerhard Frey, Ana Paula G. Cugnetti, Haizhen Liu, Charles Xing, Christina Wheeler, Hwai Wen Chang, William J. Boyle, Jay M. Short

Subjects: Get full text

Effective cancer immunotherapy combining mRNA-encoded bispecific antibodies that induce polyclonal T cell engagement and PD-L1-dependent 4-1BB costimulation by Oana Hangiu, Oana Hangiu, Oana Hangiu, Rocío Navarro, Susana Frago, Laura Rubio-Pérez, Laura Rubio-Pérez, Laura Rubio-Pérez, Antonio Tapia-Galisteo, Antonio Tapia-Galisteo, Antonio Tapia-Galisteo, Laura Díez-Alonso, Laura Díez-Alonso, Laura Díez-Alonso, Marina Gómez-Rosel, Marina Gómez-Rosel, Marina Gómez-Rosel, Noelia Silva-Pilipich, Noelia Silva-Pilipich, Lucía Vanrell, Cristian Smerdou, Cristian Smerdou, Kenneth A. Howard, Laura Sanz, Luis Álvarez-Vallina, Luis Álvarez-Vallina, Luis Álvarez-Vallina, Marta Compte

Subjects: “…T-cell engager…”
Get full text

Tarlatamab and the Future of Immunotherapy: A New Approach to Small Cell Lung Cancer by Raza Ur Rehman, MBBS, Ahmad Furqan Anjum, MBBS, Rida Fatima, MBBS

Subjects: “…Bispecific T-cell engager…”
Get full text

Engineered T cells secreting αB7-H3-αCD3 bispecific engagers for enhanced anti-tumor activity against B7-H3 positive multiple myeloma: a novel therapeutic approach by Punchita Rujirachaivej, Teerapong Siriboonpiputtana, Kornkan Choomee, Kamonlapat Supimon, Thanich Sangsuwannukul, Pucharee Songprakhon, Krissada Natungnuy, Piriya Luangwattananun, Pornpimon Yuti, Mutita Junking, Pa-thai Yenchitsomanus

Subjects: Get full text

Mechanistic PKPD modeling to describe cytokine release associated with CD3 T-cell engager therapies by Apolline Lefèvre, Apolline Lefèvre, Zinnia P. Parra-Guillen, Zinnia P. Parra-Guillen, Iñaki F. Trocóniz, Iñaki F. Trocóniz, Iñaki F. Trocóniz, Christophe Boetsch, Nicolas Frances

Subjects: Get full text

Elevated LIF and JAK-STAT activation drive severe COVID-19 in myeloma patients receiving the BCMA-CD3 bispecific antibody Elranatamab by Ziping Li, Fujing Zhang, Xianghong Jin, Junling Zhuang

Subjects: Get full text

Bi-specific autoantigen-T cell engagers as targeted immunotherapy for autoreactive B cell depletion in autoimmune diseases by Luca Perico, Federica Casiraghi, Fabiane Sônego, Marta Todeschini, Daniela Corna, Domenico Cerullo, Anna Pezzotta, Patricia Isnard-Petit, Silvia Faravelli, Federico Forneris, Kader Thiam, Ariela Benigni, Giuseppe Remuzzi

Subjects: “…bi-specific autoantigen-T cell engagers…”
Get full text

Corrigendum: Bi-specific autoantigen-T cell engagers as targeted immunotherapy for autoreactive B cell depletion in autoimmune diseases by Luca Perico, Federica Casiraghi, Fabiane Sônego, Marta Todeschini, Daniela Corna, Domenico Cerullo, Anna Pezzotta, Patricia Isnard-Petit, Silvia Faravelli, Federico Forneris, Kader Thiam, Ariela Benigni, Giuseppe Remuzzi

Subjects: “…bi-specific autoantigen-T cell engagers…”
Get full text